Summary & Overview
HCPCS J9332: Injection, efgartigimod alfa-fcab, 2mg
HCPCS Level II code J9332 identifies the injectable biologic efgartigimod alfa-fcab at a 2 mg unit. As a drug-specific HCPCS code, J9332 is used on claims to report supply and administration of this therapeutic agent, supporting billing, utilization tracking, and payer coverage determinations for infusion- or injection-based care. Nationally, accurate use of HCPCS drug codes matters for payment integrity, clinical supply management, and monitoring uptake of newer biologic therapies.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context and service setting, expected payers, typical modifiers used with HCPCS drug codes, and guidance on where to find additional coding and coverage details. The publication summarizes benchmarking and policy-relevant topics such as payer coverage patterns, billing practices for injectable biologics, and documentation elements commonly required by major payers. Data not provided in the input (for example, precise payer fee schedules, associated taxonomies, or ICD-10 pairings) are noted as unavailable. The piece is intended for billing managers, revenue-cycle staff, and clinicians involved in administering and coding injectable biologic therapies.
Billing Code Overview
HCPCS Level II code J9332 represents the medication injection, efgartigimod alfa-fcab, 2mg. This code denotes administration of efgartigimod alfa-fcab formulated for injection.
-
Service type: Drug administration (therapeutic biologic injection)
-
Typical site of service: Infusion center, outpatient clinic, or physician office capable of administering injectable biologic therapies
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with generalized myasthenia gravis experiencing increased circulating pathogenic IgG autoantibodies against the acetylcholine receptor or related proteins. The patient has been evaluated by a neuromuscular specialist and meets criteria for treatment with efgartigimod alfa-fcab due to symptomatic weakness despite conventional therapies (e.g., pyridostigmine, corticosteroids, or steroid-sparing immunosuppressants) or as an alternative when rapid reduction of pathogenic IgG levels is clinically indicated. The clinical workflow includes: referral and baseline evaluation (neurologic exam, quantitative myasthenia gravis score), baseline labs (CBC, CMP, hepatitis B/C, tuberculosis screening as indicated), insurance preauthorization for J9332, scheduling of outpatient infusion or injection services, administration of efgartigimod alfa-fcab by an experienced infusion nurse or qualified clinician, observation for infusion- or injection-related reactions for a monitored period, documentation of lot number and vial units administered, and follow-up assessments for treatment response and adverse events with dose scheduling per manufacturer guidance.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |